Revenue from contracts with customers (Tables)

9 Months Ended

Sep. 30, 2026

Revenue from Contract with Customer [Abstract]

Summary of Disaggregates Revenues by Major Revenue Streams

The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.

In alignment with Teva's Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under Teva’s United States segment. As a result, from that date, Anda is reported as part of the Company’s Other Activities. Prior period amounts were recast to reflect this change.


	Three months ended September 30, 2026
	United States		Europe		International Markets		Other Activities		Total
	(U.S.$ in millions)
Sale of goods	$	1,848	$	1,258	$	521	$	113	$	3,740
Licensing arrangements	22		14		13		§		49
Distribution	—		§		20		401		421
Other	§		46		38		99		184
	$	1,870	$	1,319	$	592	$	613	$	4,395

________

§ Represents an amount less than $0.5 million.


	Three months ended September 30, 2025
	United States		Europe		International Markets		Other Activities		Total
	(U.S.$ in millions)
Sale of goods	$	2,063	$	1,207	$	512	$	125	$	3,907
Licensing arrangements	27		11		5		3		46
Distribution	—		§		14		392		406
Other	§		16		26		78		121
	$	2,090	$	1,235	$	557	$	598	$	4,480

__________

§ Represents an amount less than $0.5 million.


	Nine months ended September 30, 2026
	United States		Europe		International Markets		Other Activities		Total
	(U.S.$ in millions)
Sale of goods	$	5,045	$	3,823	$	1,523	$	340	$	10,731
Licensing arrangements	61		37		28		1		126
Distribution	—		1		59		1,193		1,252
Other	1		62		56		291		410
	$	5,106	$	3,922	$	1,666	$	1,824	$	12,519


	Nine months ended September 30, 2025
	United States		Europe		International Markets		Other Activities		Total
	(U.S.$ in millions)
Sale of goods	$	5,332	$	3,681	$	1,535	$	389	$	10,937
Licensing arrangements	78		27		20		3		128
Distribution	—		1		36		1,130		1,167
Other	3		18		43		251		314
	$	5,413	$	3,726	$	1,634	$	1,774	$	12,547

Summary of Sales Reserves and Allowances

The changes in SR&A for third-party sales for the nine months ended September 30, 2026 and 2025 were as follows:


	Sales Reserves and Allowances
	Reserves included in Accounts Receivable, net		Rebates		Medicaid and other governmental allowances		Chargebacks		Returns		Other		Total reserves included in Sales Reserves and Allowances		Total
	(U.S.$ in millions)
Balance at January 1, 2026	$	63	$	1,954	$	701	$	937	$	445	$	106	$	4,143	$	4,206
Provisions related to sales made in current year period	287		3,619		926		5,823		203		48		10,619		10,906
Provisions related to sales made in prior periods	—		(78)		(32)		(6)		(23)		(3)		(142)		(142)
Credits and payments	(288)		(3,606)		(874)		(5,888)		(226)		(32)		(10,626)		(10,914)
Translation differences	—		(24)		(4)		(5)		(2)		(4)		(39)		(39)
Balance at September 30, 2026	$	62	$	1,865	$	717	$	861	$	397	$	115	$	3,955	$	4,017


	Sales Reserves and Allowances
	Reserves included in Accounts Receivable, net		Rebates		Medicaid and other governmental allowances		Chargebacks		Returns		Other		Total reserves included in Sales Reserves and Allowances		Total
	(U.S.$ in millions)
Balance at January 1, 2025	$	56	$	1,674	$	561	$	936	$	399	$	108	$	3,678	$	3,734
Provisions related to sales made in current year period	310		3,746		753		6,012		213		120		10,844		11,154
Provisions related to sales made in prior periods	—		(38)		33		(29)		(3)		(11)		(48)		(48)
Credits and payments	(295)		(3,432)		(701)		(6,062)		(168)		(93)		(10,456)		(10,751)
Translation differences	—		61		16		18		5		16		116		116
Balance at September 30, 2025	$	71	$	2,011	$	662	$	875	$	446	$	140	$	4,134	$	4,205